Ultra-High Performance Method on Superficially Porous Stationary Phase for the Determination of Related Substances in Pitavastatin Calcium by HPLC

Hariram, B.; Kumar, Ramesh; Anireddy, Jaya Shree; Rao, Dama Venugopala; Kalyanaraman, L.; Srinivas, K.

doi:10.1007/s10337-015-2922-y

Cited by 6 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As represented in Figure 4c, zein is an amphoteric protein carrying a net positive charge at a pH lower than its isoelectric point (pI; 6.8) and a net negative charge above its pI [64]. Pitavastatin is a weakly acidic drug with a pKa value of 4.1, so it carries a net negative charge above its pKa [65]. At alkaline pH values above 7, both zein and pitavastatin carried negative charges and, hence, electrostatic repulsion occurred, resulting in higher release rates.…”

Section: In Vitro Release Studymentioning

confidence: 99%

Dual-Drug Delivery via Zein In Situ Forming Implants Augmented with Titanium-Doped Bioactive Glass for Bone Regeneration: Preparation, In Vitro Characterization, and In Vivo Evaluation

et al. 2022

View full text Add to dashboard Cite

In situ forming implants (IFIs) are non-surgical approach using biodegradable polymers to treat bone fractures. The study aimed at preparing dual-drug-loaded IFIs to deliver pitavastatin (osteogenic drug) and tedizolid (antibiotic) using zein as the implant matrix via solvent-induced phase inversion method. At first, several investigations were done on pitavastatin-loaded zein IFIs, where three concentrations of zein were used (10, 20, and 30% w/v). IFIs were evaluated for their solidification time, rheological properties, injectability, and in vitro release. IFIs containing bioactive glass nanoparticles were prepared by the addition of non-doped bioactive glass nanoparticles (BGT0; 1, 3, 5, and 10% w/v) or titanium-doped bioactive glass nanoparticles (BGT5; 1% w/v) to the selected concentration of zein (30% w/v) and then evaluated. The optimized dual-medicated implant (D-ZIFI 1) containing pitavastatin, tedizolid, sodium hyaluronate (3% w/v), and BGT5 (1% w/v) was prepared and compared to IFI lacking both sodium hyaluronate and BGT5 (D-ZIFI 2). D-ZIFI 1 and 2 sustained the release profiles of both drugs for 28 days. SEM images proved the interconnected porous structure of D-ZIFI 1 due to sodium hyaluronate. In vivo studies on surgically induced bone defects in Sprague–Dawley rats signified the proper accelerated bone healing ability of D-ZIFI 1 over D-ZIFI 2. Results presented D-ZIFI 1 as a promising, effective, non-surgical approach for bone healing.

show abstract

Section: In Vitro Release Studymentioning

confidence: 99%

Dual-Drug Delivery via Zein In Situ Forming Implants Augmented with Titanium-Doped Bioactive Glass for Bone Regeneration: Preparation, In Vitro Characterization, and In Vivo Evaluation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The literature survey revealed that several chromatographic methods such as HPLC coupled to UV and fluorescence detectors as well as LC-MS/MS have been developed for the determination of valsartan or pitavastatin in pharmaceutical formulations and biological samples such as plasma and urine [7][8][9][10][11][12][13][14][15]. These methods suffer from limitations such as complexity, high cost, time-consuming sample preparation, and the use of hazardous chemicals.…”

Section: Introductionmentioning

confidence: 99%

Determination of valsartan and pitavastatin using synchronous spectrofluorimetry and augmented least squares chemometric models: A comparative study with greenness and blueness assessment

Almalki,

Abduljabbar,

Alzhrani

et al. 2024

Luminescence

View full text Add to dashboard Cite

Hypertension and hyperlipidemia are two common conditions that require effective management to reduce the risk of cardiovascular diseases. Among the medications commonly used for the treatment of these conditions, valsartan and pitavastatin have shown significant efficacy in lowering blood pressure and cholesterol levels, respectively. In this study, synchronous spectrofluorimetry coupled to chemometric analysis tools, specifically concentration residual augmented classical least squares (CRACLS) and spectral residual augmented classical least squares (SRACLS), was employed for the determination of valsartan and pitavastatin simultaneously. The developed models exhibited excellent predictive performance with relative root mean square error of prediction (RRMSEP) of 2.253 and 2.1381 for valsartan and pitavastatin, respectively. Hence, these models were successfully applied to the analysis of synthetic samples and commercial formulations as well as plasma samples with high accuracy and precision. Besides, the greenness and blueness profiles of the determined samples were also evaluated to assess their environmental impact and analytical practicability. The results demonstrated excellent greenness and blueness scores with AGREE score of 0.7 and BAGI score of 75 posing the proposed method as reliable and sensitive approach for the determination of valsartan and pitavastatin with potential applications in pharmaceutical quality control, bioanalytical studies, and therapeutic drug monitoring.

show abstract

A New Ecological RP-HPLC Method for the Determination of Pitavastatin, Fenofibrate and Their Impurities in a Novel Fixed Dose Combination

2022

View full text Add to dashboard Cite

Ultra-High Performance Method on Superficially Porous Stationary Phase for the Determination of Related Substances in Pitavastatin Calcium by HPLC

Cited by 6 publications

References 18 publications

Dual-Drug Delivery via Zein In Situ Forming Implants Augmented with Titanium-Doped Bioactive Glass for Bone Regeneration: Preparation, In Vitro Characterization, and In Vivo Evaluation

Dual-Drug Delivery via Zein In Situ Forming Implants Augmented with Titanium-Doped Bioactive Glass for Bone Regeneration: Preparation, In Vitro Characterization, and In Vivo Evaluation

Determination of valsartan and pitavastatin using synchronous spectrofluorimetry and augmented least squares chemometric models: A comparative study with greenness and blueness assessment

A New Ecological RP-HPLC Method for the Determination of Pitavastatin, Fenofibrate and Their Impurities in a Novel Fixed Dose Combination

Contact Info

Product

Resources

About